Sotagliflozin

Chemical formula: C₂₁H₂₅ClO₅S  Molecular mass: 424.94 g/mol  PubChem compound: 24831714

Therapeutic indications

Sotagliflozin is indicated for:

Risk of cardiovascular death, hospitalization for heart failure or urgent heart failure visit

Population group: only adults (18 years old or older)

Sotagliflozin is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

  • heart failure or
  • type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Sotagliflozin is contraindicated in the following cases:

Major surgery, procedures associated with prolonged fasting

Surgical procedure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: ZYNQUISTA Film-coated tablet
Structured Product Labeling (SPL/PLR) 2023: INPEFA Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈